Sleep Apnea

Is Sleep Apnea Dangerous? Risks and Side Effects

Untreated sleep apnea carries substantial cardiovascular, metabolic, and neurological risks. Here's what the evidence shows and why early treatment matters.

By The Sleep Editorial Team·August 2, 2025·8 min read·Reviewed by Dr. James Whitfield, MD, Sleep Medicine

Is sleep apnea dangerous risks — Photograph for Sleep Editorial.

Obstructive sleep apnea is among the most medically significant sleep disorders — not simply because it fragments sleep and impairs daytime functioning, but because of what it does to the body's most vital systems during the hours it goes untreated. Each apnea episode is a physiological stress event: oxygen saturation falls, carbon dioxide accumulates, the sympathetic nervous system fires an emergency arousal response, heart rate and blood pressure spike, and the process repeats — sometimes hundreds of times per night. The cumulative damage from years of this nightly assault on the cardiovascular, metabolic, and neurological systems is substantial and well-documented. Understanding the risks is not meant to alarm — effective treatment exists — but to convey why diagnosis and treatment matter.

Established Health Risks of Untreated Sleep Apnea

Hypertension — including resistant hypertension that doesn't respond to multiple medications
Coronary artery disease and increased heart attack risk
Stroke — both ischemic and hemorrhagic
Atrial fibrillation and other cardiac arrhythmias
Type 2 diabetes and insulin resistance
Cognitive impairment, memory problems, and accelerated dementia risk
Motor vehicle and workplace accidents from excessive daytime sleepiness

Cardiovascular risks: the most serious consequence

The cardiovascular system bears the most documented burden of untreated obstructive sleep apnea. The mechanism is well understood: each apnea episode triggers a surge in sympathetic nervous system activity as the brain rouses the body to resume breathing. This produces an acute spike in heart rate and blood pressure. With moderate-to-severe apnea, this can happen 30 or more times per hour, 7 hours per night, 365 nights per year. Over time, this sustained sympathetic activation produces structural and functional changes throughout the cardiovascular system.

Hypertension is the most common cardiovascular consequence. Approximately 50% of people with obstructive sleep apnea have hypertension, and sleep apnea is the most common identifiable secondary cause of resistant hypertension — blood pressure that fails to normalize despite three or more antihypertensive medications. The association is dose-dependent: higher apnea-hypopnea index scores correlate with greater blood pressure elevation. Multiple major cardiology guidelines now recommend screening for sleep apnea in all patients with resistant hypertension.

The risk of coronary artery disease is elevated by approximately 30–50% in untreated severe sleep apnea compared with the general population, even after controlling for shared risk factors like obesity. The mechanisms include endothelial dysfunction, increased oxidative stress from repeated hypoxia-reoxygenation cycles, elevated inflammatory markers, and the direct hemodynamic stress of repeated nocturnal blood pressure surges. People with sleep apnea who have established coronary artery disease have worse outcomes than those without apnea.

Atrial fibrillation has a particularly strong relationship with sleep apnea. Studies consistently find that 50–80% of patients with atrial fibrillation also have sleep apnea, and that untreated sleep apnea significantly increases the rate of recurrence after cardioversion or catheter ablation. Treating sleep apnea in patients with atrial fibrillation improves arrhythmia control. The mechanism involves nocturnal hypoxia, sympathetic activation, and the mechanical effects of respiratory effort against a closed airway producing negative intrathoracic pressure that directly stresses the atrial walls.

Stroke risk

The relationship between sleep apnea and stroke is bidirectional. Untreated sleep apnea is an independent risk factor for both ischemic and hemorrhagic stroke, with hazard ratios in the range of 1.5–2.0 after adjustment for conventional stroke risk factors. The mechanisms are multiple: hypertension, atrial fibrillation (a major embolic stroke risk factor), hypercoagulability from increased platelet aggregation, and impaired cerebrovascular autoregulation all contribute. The early morning hours — when oxygen desaturation from apnea peaks and blood pressure surges on awakening — represent the highest-risk window for acute vascular events, consistent with the circadian pattern of both heart attack and stroke.

Sleep apnea also commonly develops after stroke, and post-stroke sleep apnea impairs neurological recovery, rehabilitation outcomes, and increases the risk of recurrent vascular events. This means sleep apnea is not merely a risk factor for a first stroke but a potentially modifiable factor in the rehabilitation trajectory after one has occurred. Screening for sleep apnea after stroke is increasingly incorporated into comprehensive stroke care protocols at major centers.

Metabolic consequences: diabetes and weight

Sleep apnea and metabolic dysfunction are closely intertwined, in part because obesity is the primary risk factor for both — but the relationship extends beyond this shared cause. Intermittent hypoxia, the hallmark physiological insult of sleep apnea, directly impairs glucose metabolism and insulin sensitivity independent of body weight. Studies using animal models of intermittent hypoxia demonstrate dose-dependent insulin resistance even in lean subjects. In humans, the severity of oxygen desaturation correlates with the degree of insulin resistance after controlling for body mass index.

Type 2 diabetes is present in approximately 30% of patients with obstructive sleep apnea. Conversely, sleep apnea affects a substantial proportion of people with type 2 diabetes, and the sleep fragmentation produced by apnea further impairs glucose control through disruption of counter-regulatory hormone release and increased cortisol secretion. The practical implication is that for patients with type 2 diabetes who struggle with glycemic control despite optimal medical management, undiagnosed sleep apnea may be a contributing factor that, when treated, can meaningfully improve metabolic outcomes.

Cognitive and neurological effects

The brain is exquisitely sensitive to oxygen deprivation, and repeated nocturnal hypoxia leaves a measurable neurological footprint. Neuroimaging studies consistently find gray matter loss in prefrontal cortical regions, the hippocampus, and other areas associated with memory, executive function, and emotional regulation in patients with untreated sleep apnea. These structural changes correlate with cognitive test performance: attention, working memory, processing speed, and executive function are all impaired in moderate-to-severe untreated OSA, with effect sizes similar to those seen in mild cognitive impairment.

Of particular concern is the emerging evidence linking untreated sleep apnea to accelerated Alzheimer's disease risk. Amyloid-beta, one of the proteins that accumulates in Alzheimer's disease, is cleared from the brain primarily during deep slow-wave sleep via the glymphatic system. Sleep apnea severely disrupts slow-wave sleep, reducing this clearance. Multiple longitudinal studies have found that sleep apnea is associated with earlier onset of cognitive impairment and Alzheimer's disease, and that effective CPAP treatment attenuates the rate of cognitive decline in apnea patients. While causality remains under investigation, the biological plausibility is strong and the potential public health implications significant.

The accident risk: daytime sleepiness and safety

Excessive daytime sleepiness, the most immediately apparent functional consequence of untreated sleep apnea, poses direct safety risks that should not be underestimated. Studies consistently find that people with untreated obstructive sleep apnea have 2–3 times the risk of a motor vehicle accident compared with the general driving population. The impairment of reaction time, vigilance, and decision-making produced by the chronic sleep deprivation of untreated apnea is comparable to that produced by moderate alcohol intoxication. Many patients have learned to compensate and underestimate their impairment, which makes the risk particularly difficult to self-assess.

Workplace accidents and injuries also occur at elevated rates in untreated sleep apnea patients, with particular significance in safety-sensitive occupations including commercial transportation, aviation, construction, and healthcare. Regulatory bodies in several countries have implemented mandatory sleep apnea screening for commercial drivers. Recognition of this risk in other high-stakes occupations is increasing.

Does treating sleep apnea reduce these risks?

For cardiovascular risk, the evidence is clearest for hypertension: CPAP therapy produces modest but statistically significant reductions in both systolic and diastolic blood pressure, particularly in patients with resistant hypertension. For stroke and cardiac events, observational studies consistently find reduced event rates in adherent CPAP users, though definitive randomized trial evidence for hard cardiovascular endpoints has been more difficult to establish — primarily because randomized trials are ethically and practically challenging when the intervention is proven to improve symptoms. The preponderance of evidence from large observational studies with long follow-up periods supports a protective effect of treatment on cardiovascular outcomes.

For cognitive function, CPAP therapy produces measurable improvements in attention, executive function, and mood, with the greatest gains in patients who use therapy most consistently. For accident risk, treated patients' motor vehicle accident rates fall to approximately population norms. For metabolic outcomes, the evidence is mixed: CPAP improves some metabolic parameters but does not substitute for weight management and diabetes treatment.

Frequently Asked Questions

How quickly do health risks develop with untreated sleep apnea?

Cardiovascular and metabolic consequences develop over years, though some physiological changes — elevated blood pressure, increased inflammatory markers, insulin resistance — may be measurable relatively early in the course of untreated apnea. The cumulative burden is dose-dependent: more severe apnea, measured by apnea-hypopnea index and degree of oxygen desaturation, produces greater risk and faster accumulation of harm. Younger patients may tolerate the condition better initially but face a longer duration of exposure to its effects.

Can losing weight cure sleep apnea?

Significant weight loss — particularly through bariatric surgery or GLP-1 receptor agonist medications — can dramatically reduce or resolve obstructive sleep apnea in obese patients. Studies of bariatric surgery have found resolution or substantial improvement in apnea severity in 50–80% of cases. However, complete resolution without weight loss is uncommon for moderate-to-severe apnea, and structural anatomical factors may sustain apnea even after significant weight loss. Weight management is an important complementary strategy, not a replacement for treatment.

Is sleep apnea related to depression?

Yes. Depression is significantly more prevalent in people with obstructive sleep apnea than in the general population, and the relationship appears bidirectional. Untreated sleep apnea impairs mood, motivation, cognitive function, and quality of life in ways that produce or worsen depressive symptoms. Conversely, depression may reduce sleep quality and respiratory muscle tone in ways that exacerbate apnea. Several studies have found that effective CPAP treatment reduces depressive symptoms, and some patients with treatment-resistant depression improve after sleep apnea is identified and treated.

Does sleep apnea affect lifespan?

Untreated severe obstructive sleep apnea is associated with increased all-cause mortality in longitudinal studies, primarily driven by cardiovascular events. A frequently cited study found that men under 50 with severe untreated sleep apnea had significantly higher mortality rates over an 18-year follow-up compared with those without apnea. Effective treatment substantially attenuates this risk. The mortality association is strongest for severe apnea with significant nocturnal oxygen desaturation.

What is the most effective treatment for sleep apnea?

Continuous positive airway pressure (CPAP) therapy remains the most effective treatment for moderate-to-severe obstructive sleep apnea. When used consistently, CPAP eliminates apneas, restores normal oxygen saturation, resolves sleep fragmentation, and dramatically reduces daytime sleepiness. For mild apnea or patients who cannot tolerate CPAP, oral appliances that advance the lower jaw are a validated alternative with slightly lower efficacy. Positional therapy, weight loss, and upper airway surgery are also effective in appropriate candidates. A sleep medicine specialist can help determine the best treatment approach for an individual's anatomy, apnea severity, and preferences.

Moving Forward

The research landscape on this topic has matured to the point where clear, evidence-based recommendations are available — and where the gap between what the evidence shows and what most people actually receive as treatment remains an important public health problem. Understanding the research, seeking the appropriate treatment for your specific situation, and following through with the behavioral work that evidence-based protocols require are the three steps most likely to produce lasting improvement. The evidence is clear; the access is increasingly available; the work, for those who commit to it, produces results that medication alone cannot match over time.

For anyone still in the early stages of understanding their sleep problem — not yet sure whether what they have is clinical insomnia, a physiological disorder, a circadian issue, or simply inadequate sleep opportunity — the most productive next step is a two-week sleep diary and a conversation with a physician who can review it in clinical context. From that foundation, the appropriate next intervention becomes considerably clearer.

The Behavioral Sleep Component Still Needs Attention

Weight loss through GLP-1 medications can meaningfully reduce OSA severity by decreasing parapharyngeal fat and improving airway caliber — but even significant weight loss rarely eliminates the behavioral insomnia that has developed over years of fragmented sleep. Conditioned arousal, excessive time in bed, and sleep-performance anxiety are independent of body weight and persist until specifically addressed. Sleep Reset is a digital CBT-I program that directly targets these behavioral and cognitive patterns, and can be used alongside any medical weight-loss or OSA treatment program without conflict.

Disclosure

Sleep Editorial is an independent publication. This article reflects the editorial team's independent assessment. Sleep Editorial does not provide medical advice; consult a qualified clinician for diagnosis and treatment.